PIK3CA and cancer: A valuable route to implement the successful development of metformin as an anti-cancer drug might involve PK/PD modeling of metformin in type 2 diabetics enrolled in early research phases of other oncology discovery projects involving metformin-related molecular targets (e.g., inhibitors of mTOR, PI3K) [22–24].